Natalia Berry, MD
Cardiovascular Disease · Lebanon, NHNPI 1780810291
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,805 of the $3,006 with a category attached, or 60.0%. Edwards Lifesciences accounts for 87.0% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $2,850, more than ten times the $45 reported in 2019.
Across 17 payments — averaging $176.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$3K
- Medtronic$307
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$23
- Abbott$22
- Spectrawave, Inc$19
- Boston Scientific$18
Across 13 payments — averaging $3226.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$32K
- Biotronik Inc.$10K
- Boston Scientific$150
What the payments were for
- Travel & lodging$1,80560%
- Food & beverage$1,20240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 11 | $2,616 |
| Medtronic | 2 | $307 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $23 |
| Abbott | 1 | $22 |
| Spectrawave, Inc | 1 | $19 |
| Boston Scientific | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVOQUE$1,210
- COREVALVE EVOLUT R$307
How this compares
$3,006 in reported general payments places this provider in the 70th percentile of 112 cardiovascular disease providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $23,014 |
| EntrestoSacubitril/Valsartan | 19 | $21,326 |
| Repatha SureclickEvolocumab | 18 | $20,187 |
| PradaxaDabigatran Etexilate Mesylate | 29 | $8,117 |
| JardianceEmpagliflozin | 16 | $7,583 |
| Metoprolol Tartrate | 80 | $832 |
| ClopidogrelClopidogrel Bisulfate | 43 | $793 |
| Atorvastatin Calcium | 60 | $762 |
| Furosemide | 57 | $605 |
| Losartan Potassium | 25 | $315 |
| Carvedilol | 23 | $233 |
| Amlodipine Besylate | 22 | $230 |
| Metoprolol Succinate | 17 | $214 |
| Spironolactone | 20 | $185 |
| Lisinopril | 14 | $167 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Lebanon
- Kevin KwakuLebanon$79K
- Michael YoungLebanon$53K
- Merle MyersonLebanon$15K
- Ian GilchristLebanon$13K
- Robert DangeloLebanon$10K
- Rumman SyedLebanon$9K
- Mohammadtokir MujtabaLebanon$8K
- Lauren Gilstrap MilleyLebanon$5K
- Fernando Contreras-ValdesLebanon$5K
- David MinLebanon$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.